Health Catalyst, Inc.
NASDAQ:HCATMedical - Healthcare Information Services
-$0.04 today
- Market cap
- $98.24M
- Beta
- 1.66
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$3.65
Volume 0.27M
Average 1.24M
HCAT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Health Catalyst, Inc.NASDAQ: HCAT
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $591K (cash outflow) fell 90.3% year over year, behind the +163.3% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 0.6% of revenue in FY2025, down 0.8 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -90.3% toward the trailing-twelve-month pace of +163.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (1.81M) USD
- Year-over-year change
- -142.3%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.81M) | -142.3% |
| FY2024 | 2024-12-31 | 4.28M | +131.3% |
| FY2023 | 2023-12-31 | (13.66M) | -1833.9% |
| FY2022 | 2022-12-31 | 788K | +672.5% |
| FY2021 | 2021-12-31 | 102K | — |
Accounts Receivables vs competitors
How HCAT compares with its peers on the latest reported figures
- HCAT's LTM Mar 2026 accounts receivables of $3.67M is the 4th largest of the 11 companies compared; the peer median is $2.5K.
- Its year-over-year change of +163.3% is the 4th highest of 9, against a peer median of +114.7%.
- Accounts receivables amounts to 1.2% of revenue for HCAT, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.8M | +4000.1% | +39.1% | 47.4% | |
| LTM Mar 2026 | $10.63M | — | — | 4723.1% | |
| LTM Mar 2026 | $8.65M | +7764.5% | — | 7.4% | |
| LTM Mar 2026 | $3.67M | +163.3% | — | 1.2% | |
| LTM Mar 2026 | $3M | -137.5% | — | 21.6% | |
| LTM Mar 2026 | $2.34M | +94.0% | +9.5% | 5.3% | |
| LTM Mar 2026 | $378K | -56.7% | -57.2% | 3.4% | |
| LTM Mar 2026 | $133K | -337.5% | — | 1.4% | |
| LTM Dec 2025 | $113.84K | +135.5% | +13.1% | 0.9% | |
| LTM Mar 2026 | $5K | +171.4% | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding HCAT) | $2.5K | +114.7% | +11.3% | 4.3% | |
Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (153.21M) | (137.4M) | (118.15M) | (69.5M) | (177.97M) |
| Depreciation & Amortization | 37.53M | 48.3M | 42.22M | 41.43M | 50.5M |
| Deferred Income Tax | (7.13M) | (4.52M) | 8K | 77K | 81K |
| Stock-Based Compensation | 65.15M | 72.1M | 55.76M | 40.13M | 27.01M |
| Change in Working Capital | 4.62M | (13.91M) | (13.67M) | (660K) | (15.11M) |
| Accounts Receivables | 102K | 788K | (13.66M) | 4.28M | (1.81M) |
| Inventory | (8.33M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 5.2M | (4.7M) | 4.87M | 5.58M | (11.51M) |
| Other Working Capital | 7.64M | (9.99M) | (4.88M) | (10.52M) | (1.79M) |
| Other Non-Cash Items | 29.93M | 162K | 750K | 3.09M | 116.22M |
| Operating Cash Flow | (23.12M) | (35.27M) | (33.08M) | 14.56M | 731K |
| Capital Expenditures | (18.47M) | (17.41M) | (14.31M) | (16.4M) | (968K) |
| Acquisitions (Net) | (46.76M) | (27.85M) | (11.39M) | (80.28M) | (41.11M) |
| Purchases of Investments | (261.36M) | (308.96M) | (290.84M) | (168.31M) | (65.13M) |
| Sales of Investments | 186.89M | 315.17M | 336.8M | 242.07M | 163.95M |
| Other Investing Activities | 22K | (15.22M) | (13.04M) | (14.77M) | (20.54M) |
| Investing Cash Flow | (139.68M) | (39.02M) | 20.29M | (22.9M) | 36.19M |
| Debt Repayment | 0 | 0 | 0 | 151.32M | (232.29M) |
| Common Stock Issued | 245.18M | 0 | 0 | 2.58M | 1.51M |
| Common Stock Repurchased | 0 | (8.39M) | (1.81M) | 0 | (5M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 18.9M | 5.78M | 4.54M | (2.15M) | 0 |
| Financing Cash Flow | 264.08M | (2.61M) | 2.73M | 151.75M | (235.78M) |
| Effect of Forex Changes | (10K) | (11K) | 21K | (34K) | 27K |
| Net Change in Cash | 101.27M | (76.92M) | (10.04M) | 143.37M | (198.83M) |
| Free Cash Flow | (41.59M) | (52.68M) | (47.39M) | (1.84M) | (237K) |
Health Catalyst, Inc.
NASDAQ:HCAT
Intrinsic Alpha fair value
Locked
Current Price
$1.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.